In a report issued on February 28, Dariusz Ubik from Kepler Capital maintained a Hold rating on Grifols SA (GRFS – Research Report), with a price target of EUR22.90. The company’s shares closed last Tuesday at $12.33.
According to TipRanks.com, Ubik is ranked #6570 out of 7793 analysts.
The word on The Street in general, suggests a Hold analyst consensus rating for Grifols SA with a $19.08 average price target.
The company has a one-year high of $19.07 and a one-year low of $10.10. Currently, Grifols SA has an average volume of 827.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.
Read More on GRFS:
- Fabasoft AG (FBSFF) Receives a Buy from Warburg Research
- Barclays Sticks to Its Buy Rating for Sovos Brands (SOVO)
- Barclays Reaffirms Their Hold Rating on Beam Therapeutics (BEAM)
- Barclays Sticks to Their Buy Rating for Ingersoll Rand (IR)
- Liberty Media Liberty Formula One (FWONK) Gets a Sell Rating from Barclays